Last reviewed · How we verify

Rocuronium emergency surgery

Diskapi Yildirim Beyazit Education and Research Hospital · Phase 3 active Small molecule

Rocuronium is a neuromuscular blocking agent that competitively binds to acetylcholine receptors at the neuromuscular junction, preventing muscle contraction.

Rocuronium is a neuromuscular blocking agent that competitively binds to acetylcholine receptors at the neuromuscular junction, preventing muscle contraction. Used for Neuromuscular blockade for emergency surgery and rapid sequence intubation, Facilitation of endotracheal intubation during anesthesia.

At a glance

Generic nameRocuronium emergency surgery
Also known asesmeron
SponsorDiskapi Yildirim Beyazit Education and Research Hospital
Drug classNeuromuscular blocking agent (non-depolarizing)
TargetNicotinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhasePhase 3

Mechanism of action

Rocuronium is a non-depolarizing steroidal neuromuscular blocker that acts as a competitive antagonist at the nicotinic acetylcholine receptors on the motor end plate. By blocking acetylcholine from binding to these receptors, it prevents depolarization and muscle contraction, producing paralysis necessary for intubation and surgical procedures. Its onset is rapid (60-90 seconds) and duration is intermediate (30-40 minutes), making it suitable for emergency surgical settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results